Rockwell Medical (RMTI) Investor Presentation - Slideshow

Triferic Overview - Rockwell Medical is a commercial-stage company focused on transforming anemia management, initially targeting ESRD[7] - Triferic is designed to replace iron and maintain hemoglobin without increasing ferritin levels[7] - The global Triferic market potential is estimated to exceed $1 billion[7] Triferic Clinical and Commercial Progress - Dialysate Triferic was launched in the U S in May 2019[10] - An NDA for I V Triferic was submitted in May 2019, with a PDUFA date of March 28, 2020[10, 13] - Clinical data is being collected from seven sites with over 500 patients, with initial data expected in Q1 2020[12] - Clinics adopting Triferic have shown a 75% conversion rate since launch[18] Market and Financial Position - Rockwell Medical generates over $60 million in annual revenue from dialysis concentrates[7] - The U S market for anemia management therapies in CKD is over $4 1 billion annually[40] - The company is the 2 supplier of dialysis concentrates in the U S [7] International Expansion - Partnerships are in place for Triferic in China, India, Canada, Peru, and Chile[11] - The estimated peak market opportunity in China is over $400 million[52] - The estimated peak market opportunity in Europe and Japan is over $600 million[53]